BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25985712)

  • 21. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
    ; Lorch A; Beyer J; Bascoul-Mollevi C; Kramar A; Einhorn LH; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin KA; Lotz JP; Germa Lluch JR; Powles T; Kollmannsberger CK
    J Clin Oncol; 2010 Nov; 28(33):4906-11. PubMed ID: 20956623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
    Mead GM; Stenning SP; Parkinson MC; Horwich A; Fossa SD; Wilkinson PM; Kaye SB; Newlands ES; Cook PA
    J Clin Oncol; 1992 Jan; 10(1):85-94. PubMed ID: 1309383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
    Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
    J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
    Marwaha S; Venner PM; North SA
    Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
    Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
    J Clin Oncol; 1997 Feb; 15(2):594-603. PubMed ID: 9053482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
    Suurmeijer AJ; Oosterhuis JW; Marrink J; De Bruin HW; Schraffordt Koops H; Sleijfer DT; Fleuren GJ
    Oncodev Biol Med; 1983; 4(4):289-308. PubMed ID: 6188132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
    Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
    Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
    Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.
    Gonzalez-Billalabeitia E; Castellano D; Sobrevilla N; Guma J; Hervas D; Luengo MI; Aparicio J; Sanchez-Muñoz A; Mellado B; Saenz A; Valverde C; Fernandez A; Margeli M; Duran I; Fernandez S; Sastre J; Ros S; Maroto P; Manneh R; Cerezuela P; Carmona-Bayonas A; Ayala de la Peña F; Luis Aguilar J; Rivera S; García Del Muro X; Germà-Lluch JR;
    J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome.
    Bokemeyer C; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Einhorn L; Nichols CR; Hartmann JT
    Cancer; 2001 Apr; 91(7):1394-401. PubMed ID: 11283942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center.
    Necchi A; Giannatempo P; Lo Vullo S; Farè E; Raggi D; Marongiu M; Scanagatta P; Duranti L; Giovannetti R; Girelli L; Nicolai N; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Gianni AM; Mariani L; Pastorino U; Salvioni R
    Clin Genitourin Cancer; 2015 Feb; 13(1):87-93.e1. PubMed ID: 25044148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors.
    Baranzelli MC; Kramar A; Bouffet E; Quintana E; Rubie H; Edan C; Patte C
    J Clin Oncol; 1999 Apr; 17(4):1212. PubMed ID: 10561181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
    Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
    N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
    J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
    Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.